Rasburicase

Generic Name: Rasburicase

Brand Names: Elitek, Fasturtec

Drug Type: Biotech

CAS Number: 134774-45-1

Unique Ingredient Identifier: 08GY9K1EUO

Background: Rasburicase is a recombinant urate-oxidase enzyme produced by a genetically modified Saccharomyces cerevisiae strain. The cDNA coding for rasburicase was cloned from a strain of Aspergillus flavus.

Indication: For treatment of hyperuricemia, reduces elevated plasma uric acid levels (from chemotherapy)

Associated Conditions: Hyperuricemia

Clinical Trials

Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy

Phase 4

Completed

Conditions: Tumors
Hyperuricemia
Tumor Lysis Syndrome

First Posted Date: 2005-09-30

Last Posted Date: 2009-03-30

Lead Sponsor: Sanofi

Target Recruit Count: 94

Registration Number: NCT00230217

Locations: 🇺🇸
Alta Bates Comprehensive Cancer Center, Berkley, California, United States
🇺🇸
University of Florida Health Science Center at Jacksonville, Jacksonville, Florida, United States
🇺🇸
University of Pennsylvania Health Systems, Philadelphia, Pennsylvania, United States

and more 4 locations

Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma

Phase 3

Completed

Conditions: Adult Acute Lymphocytic Leukemia
High-grade Lymphoma

Interventions: Drug: Allopurinol
Drug: Rasburicase

First Posted Date: 2005-09-20

Last Posted Date: 2023-03-17

Lead Sponsor: Goethe University

Target Recruit Count: 80

Registration Number: NCT00199043

Locations: 🇩🇪
University Hospital, Medical Dept. II, Frankfurt, Germany

Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients

Completed

Conditions: Leukemia
Lymphoma
Tumor Lysis Syndrome
Hyperuricemia

Interventions: Drug: Rasburicase

First Posted Date: 2005-09-16

Last Posted Date: 2017-04-25

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 16

Registration Number: NCT00186940

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Stanford University, Palo Alto, California, United States

and more 8 locations

Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma

Phase 2

Completed

Conditions: Childhood Immunoblastic Large Cell Lymphoma
Childhood Diffuse Large Cell Lymphoma
Stage I Childhood Small Noncleaved Cell Lymphoma
Stage II Childhood Large Cell Lymphoma
Stage II Childhood Small Noncleaved Cell Lymphoma
Stage IV Childhood Small Noncleaved Cell Lymphoma
Stage I Childhood Large Cell Lymphoma
Stage III Childhood Large Cell Lymphoma
Stage IV Childhood Large Cell Lymphoma
Untreated Childhood Acute Lymphoblastic Leukemia

Interventions: Drug: doxorubicin hydrochloride
Drug: cyclophosphamide
Drug: methotrexate
Drug: leucovorin calcium
Drug: rasburicase
Drug: prednisone
Drug: methylprednisolone
Biological: filgrastim
Biological: rituximab
Drug: cytarabine
Drug: etoposide
Drug: vincristine sulfate
Drug: hydrocortisone sodium succinate
Other: laboratory biomarker analysis

First Posted Date: 2003-04-09

Last Posted Date: 2014-09-19

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 97

Registration Number: NCT00057811

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy